Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 12/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7080676 | 0.85 | PARP1 (0.49) | PARP1SIGMAR1MAOB | |
| Hydrochloric Acid SCHEMBL7077252 | 0.73 | PARP1 (0.48) | PARP1 | |
| SCHEMBL7080202 | 0.72 | TSHR (0.43) | PARP1 | |
| SCHEMBL7080687 | 0.71 | PARP1 (0.43) | PARP1 | |
| SCHEMBL6481336 | 0.71 | PARP1 (0.49) | PARP1 | |
| SCHEMBL6494377 | 0.71 | PARP1 (0.61) | PARP1 | |
| SCHEMBL6482839 | 0.70 | PARP1 (0.46) | PARP1 | |
| SCHEMBL6489427 | 0.69 | PARP1 (0.43) | PARP1 | |
| SCHEMBL6483093 | 0.68 | PARP1 (0.48) | PARP1 | |
| SCHEMBL20237220 | 0.66 | PARP1 (0.48) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030143341-A1 | Dieletric thin films from fluorinated benzocyclobutane precursors | DIELECTRIC SYSTEMS, INC. (US) | 2003-07-31 | — | — | US | claimed |
| US-6649618-B2 | Prevention and/or therapy of ischaemia and reperfusion damage; poly(ADP-ribose)-synthetase inhibitors | BAYER AKTIENGESELLSCHAFT (DE) | 2003-11-18 | — | — | US | disclosed |
| US-20030143341-A1 | Dieletric thin films from fluorinated benzocyclobutane precursors | DIELECTRIC SYSTEMS, INC. (US) | 2003-07-31 | — | — | US | disclosed |
| EP-1303497-A1 | SUBSTITUTED AMIDOALKYL-URACILS AS PARP INHIBITORS | Bayer Aktiengesellschaft (DE) | 2003-04-23 | — | — | EP | disclosed |
| US-20030022905-A1 | Substituted amidoalkyl-uracils and their use | BAYER AKTIENGESELLSCHAFT (DE) | 2003-01-30 | — | — | US | disclosed |
| WO-2002006247-A1 | SUBSTITUTED AMIDOALKYL-URACILS AS PARP INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022905-A1 | Substituted amidoalkyl-uracils and their use | UNG, UMPS, TYMP | PARP1 283/4885SIGMAR1 2145/4885MAOB 769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.